Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUOXEPIL trial of add-on fluoxetine for drug-resistant complex and rare pediatric epilepsy
2024-519897-38-01Phase 3Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluoxetine in epilepsy, epileptic encephalopathy, epilepsy syndrome and 1 more, sponsored by Assistance Publique–Hôpitaux de Marseille. Planned start Sep 2026; status: authorised.
02
Drugs
fluoxetine
03
Conditions
epilepsyepileptic encephalopathyepilepsy syndromestructural epilepsy
Beyond the preview
Go deeper on 2024-519897-38-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519897-38-01.